iSpecimen (ISPC) vs NRC Health (NRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NRC Health is the larger company by market cap ($533.9 million vs $2.6 million), about 202.1 times the size. NRC Health pays a dividend yielding 2.54%, while iSpecimen does not currently pay one. NRC Health converts more of its revenue into profit, with a net margin of 8.4% versus -543.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ISPC | NRC |
|---|---|---|
| Share price | $0.4563 | $25.16 |
| Market cap | $2.64M | $533.93M |
| 1-day change | -13.58% | +0.68% |
| YTD return | — | +34.04% |
| 1-year return | — | +42.47% |
| 5-year return | — | -38.98% |
| P/E ratio (TTM) | — | 93.19 |
| Forward P/E | — | 23.74 |
| EPS (TTM) | $-52.98 | $0.27 |
| Dividend yield | 0.00% | 2.54% |
| Annual dividend | $0.00 | $0.64 |
| Revenue (latest FY) | $1.93M | $137.39M |
| Revenue growth (YoY) | -79.24% | -3.96% |
| Net income (latest FY) | $-10.49M | $11.60M |
| Gross margin | 11.18% | — |
| Operating margin | -465.42% | 16.44% |
| Net margin | -543.68% | 8.44% |
| 52-week high | $27.44 | $27.60 |
| 52-week low | $0.432 | $11.74 |
| Distance from 52-week high | -98.34% | -8.84% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +7.31% |
| Average volume | 598.66K | 110.81K |
| Shares outstanding | 5.79M | 21.22M |
| Employees | 7 | 357 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRC Health is about 202.1 times larger than iSpecimen by market value ($533.93M vs $2.64M).
- NRC Health offers a meaningfully higher dividend yield (2.54% vs 0.00%).
- NRC Health is more profitable, keeping 8.4 cents of every revenue dollar as net income versus -543.7 cents for iSpecimen.
- NRC Health grew revenue faster in its latest fiscal year (-3.96% vs -79.24%).
About iSpecimen
ISPC stock →iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 7 employees
About NRC Health
NRC stock →NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 357 employees
ISPC vs NRC FAQ
Which is bigger, iSpecimen or NRC Health?
NRC Health (NRC) is larger, with a market capitalization of $533.93M compared with $2.64M for iSpecimen (ISPC).
Which pays a higher dividend, iSpecimen or NRC Health?
NRC Health pays a dividend yielding 2.54%, while iSpecimen does not currently pay a regular dividend.
Are iSpecimen and NRC Health in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.